Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Actinic Keratosis Treatment Market

Actinic Keratosis Treatment Market Trends

Report ID: GMI5859
Published Date: May 2023
Report Format: PDF

Download Free Sample

Actinic Keratosis Treatment Market Trends

Increasing number of drug approvals and the emergence of novel therapies is expected to boost market growth. For instance, in 2021, Biofrontera AG received FDA approval for its new BF-RhodoLED XL, used in combination with Ameluz for the treatment of mild and moderate actinic keratoses on the face and scalp. Similarly, in June 2020, Sun Pharmaceutical Industries Ltd received FDA approval for its LEVULAN KERASTICK, a photodynamic therapy medicine for use on the upper extremities. Thus, approval of new drugs and therapies for actinic keratosis management has expanded the range of treatment options available to healthcare providers, enhancing the effectiveness and outcomes for patients.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for actinic keratosis treatment accounted for USD 5.5 billion in 2022 and is estimated to grow at 5.5% CAGR during 2023 to 2032. Rising prevalence of actinic keratosis, coupled with growing demand for minimally invasive procedures is expected to boost the market growth.

The topical medications segment accounted over 49% market share in 2022 and is projected to witness robust growth through 2032, owing to the ability of topical medications to treat multiple AK lesions simultaneously, making them suitable for widespread or field treatment.

North America accounted for 41.6% share in actinic keratosis treatment market in 2022 and is anticipated to grow at considerably over 2023-2032, backed by well-established healthcare infrastructure in the region, along with growing awareness pertaining to various risks associated with sun exposure and regular skin examinations.

Sun Pharmaceutical Industries Ltd, Galderma S.A., Biofrontera AG, Almirall, S.A. among others.